• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (COVINGTON) -1018233 AVAULTA PLUS BIOSYNTHETIC SUPPORT SYSTEM - POSTERIOR; AVAULTA PLUS® BIOSYNTHETIC SUPPORT SYSTEM - POSTERIOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (COVINGTON) -1018233 AVAULTA PLUS BIOSYNTHETIC SUPPORT SYSTEM - POSTERIOR; AVAULTA PLUS® BIOSYNTHETIC SUPPORT SYSTEM - POSTERIOR Back to Search Results
Catalog Number 486201
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Bacterial Infection (1735); Injury (2348); Blood Loss (2597)
Event Type  Injury  
Manufacturer Narrative
The sample was not returned.The finished product met all specifications prior to being released for general distribution.The instructions for use which accompanies all devices currently addresses potential risks associated with surgically implanted materials.The instructions for use states in the adverse events: hematoma, seroma, mucosal or visceral erosion, infection, inflammation, sensitization, dyspareunia, scarification and contraction, fistula formation, extrusion and recurrence of vaginal wall prolapse.Perforations or lacerations of vessels, nerves, bladder, bowel, rectum, or any viscera may occur during needle passage.(b)(4).
 
Event Description
The patient¿s attorney alleged a deficiency against the device.Additional information has been requested, but not yet received.Per additional information received, the patient has experienced blood loss, serratia marcescens in urine (bacterial infection), urinary tract infection, incomplete emptying, slow stream, urge frequency, hematuria, urinary frequency incontinence, constipation, interstitial cystitis (inflammation), cystocele (prolapse), pelvic/adnexal pain, atrophic vaginitis (inflammation), urge incontinence, urine urgency (urinary urgency), white blood cells found in urine, burning sensation during urination (dysuria), fever, chills, tender bladder, abdominal tenderness suprapubically, multiple bladder lavages, and required nonsurgical interventions.Per additional information received, the patient further experienced lesions, stress urinary incontinence, female, and required additional surgical interventions with revision of the mesh.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AVAULTA PLUS BIOSYNTHETIC SUPPORT SYSTEM - POSTERIOR
Type of Device
AVAULTA PLUS® BIOSYNTHETIC SUPPORT SYSTEM - POSTERIOR
Manufacturer (Section D)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd
covington GA 30014
Manufacturer (Section G)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd
covington GA 30014
Manufacturer Contact
yonic anderson
8195 industrial blvd
covington, GA 30014
7707846100
MDR Report Key10227800
MDR Text Key197978740
Report Number1018233-2020-04277
Device Sequence Number1
Product Code OTP
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K082571
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type other
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 07/02/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/03/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date07/31/2008
Device Catalogue Number486201
Device Lot NumberCVRG0027
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Device Age1 MO
Event Location Hospital
Date Manufacturer Received06/18/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured07/25/2007
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age49 YR
Patient Weight128
-
-